Datta Chitraniva, Das Dharitri, Mondal Paritosh, Chakraborty Biswajit, Sengupta Mahuya, Bhattacharjee Chira R
Department of Chemistry, Assam University, Silchar 788011, Assam, India.
Department of Biotechnology, Assam University, Silchar 788011, Assam, India.
Eur J Med Chem. 2015 Jun 5;97:214-24. doi: 10.1016/j.ejmech.2015.05.005. Epub 2015 May 8.
A novel water soluble five coordinate oxovanadium(IV) complex, [VO(C16H15N4O8S)HSO4] incorporating cefuroxime, a cephalosporin group of antibiotic have been prepared from an interaction of vanadyl sulfate and cefuroxime in aqueous solution. The compound was characterized by Fourier transform infrared spectroscopy (FTIR), CHN microanalyses, ultraviolet-visible spectroscopy (UV-Vis), fast atom bombardment (FAB) mass spectrometry and thermogravimetric analysis (TGA). Density Functional Theory (DFT) computation using Gaussian 09 program at B3LYP level revealed a distorted square pyramidal energy optimized geometry for the vanadyl(IV) complex. The molecular docking studies show that the interaction between the vanadium complex and protein receptor, clathrin is dominated by hydrophobic forces. The experimental (1)H nuclear magnetic resonance (NMR) features of the analogous Zn(II) complex matched well with the theoretically computed values further affirming the distorted square pyramidal geometry for the vanadyl(IV) complex. Cyclic voltammetry revealed a metal centered single-electron oxidation-reduction response for VO(IV)/VO(V) couple. The antioxidant activity of the vanadium(IV)-complex vis-à-vis the antibiotic has been assessed by 1,1-diphenyl-2-picrylhydrazyl (DPPH) method. The vanadium complex showed comparatively better radical scavenging ability compared to the antibiotic cefuroxime. The antimicrobial activity of the compound has been assayed for five different microbial strains using minimum inhibitory concentration (MIC) method. Immunomodulatory studies carried out using phagocytosis index, myeloperoxidase release and cytokine assay indicated the vanadium(IV)-complex to be immunosuppressant. The cytotoxicity of the compound was evaluated by MTT (3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) reduction assay.
一种新型水溶性五配位氧钒(IV)配合物[VO(C₁₆H₁₅N₄O₈S)HSO₄],它结合了头孢菌素类抗生素头孢呋辛,是通过硫酸氧钒和头孢呋辛在水溶液中的相互作用制备而成的。该化合物通过傅里叶变换红外光谱(FTIR)、CHN微量分析、紫外可见光谱(UV-Vis)、快原子轰击(FAB)质谱和热重分析(TGA)进行了表征。使用高斯09程序在B3LYP水平进行的密度泛函理论(DFT)计算揭示了氧钒(IV)配合物的能量优化几何结构为扭曲的四方锥。分子对接研究表明,钒配合物与蛋白质受体网格蛋白之间的相互作用主要由疏水作用力主导。类似的锌(II)配合物的实验¹H核磁共振(NMR)特征与理论计算值匹配良好,进一步证实了氧钒(IV)配合物的扭曲四方锥几何结构。循环伏安法揭示了VO(IV)/VO(V)电对以金属为中心的单电子氧化还原响应。通过1,1-二苯基-2-苦基肼(DPPH)法评估了钒(IV)配合物相对于抗生素的抗氧化活性。与抗生素头孢呋辛相比,钒配合物表现出相对更好的自由基清除能力。使用最低抑菌浓度(MIC)法对该化合物针对五种不同微生物菌株的抗菌活性进行了测定。使用吞噬指数、髓过氧化物酶释放和细胞因子测定进行的免疫调节研究表明钒(IV)配合物具有免疫抑制作用。通过MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑)还原试验评估了该化合物的细胞毒性。